Sumitomo Pharma America Reports Promising Early Clinical Results for Investigational CHK1 Inhibitor SMP-3124LP in Advanced Solid Tumors
Sumitomo Pharma America, Inc. (SMPA) has unveiled encouraging clinical findings from its ongoing first-in-human Phase 1/2 study evaluating SMP-3124LP, an investigational checkpoint kinase 1 (CHK1) inhibitor designed to address some of the longstanding challenges associated with targeting the DNA damage response pathway in cancer. The data were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the world’s premier oncology conferences, highlighting the company’s efforts to advance innovative therapies for patients with difficult-to-treat cancers.
SMP-3124LP is a structurally distinct, highly selective CHK1 inhibitor delivered through a PEGylated liposomal formulation. The drug has been specifically engineered to target tumors characterized by high levels of replication stress, a hallmark of many aggressive cancers. By combining selective CHK1 inhibition with liposomal drug delivery technology, researchers hope to improve the therapeutic window of this class of drugs while reducing the toxicities that have historically limited their clinical development.
The newly presented findings provide the first glimpse into the therapy’s clinical performance in patients with advanced solid tumors and suggest that the novel formulation may be capable of producing meaningful antitumor activity while maintaining a manageable safety profile.
Addressing a Long-Standing Challenge in Oncology
Checkpoint kinase 1 is a critical component of the cellular DNA damage response system. The enzyme helps cells detect DNA damage and coordinate repair mechanisms that allow survival under stressful conditions. Cancer cells often rely heavily on CHK1 because they experience high levels of replication stress as a result of rapid and uncontrolled growth.
For years, researchers have viewed CHK1 as an attractive therapeutic target. By inhibiting the enzyme, scientists aim to prevent cancer cells from repairing DNA damage, ultimately leading to cell death. However, despite strong biological rationale, previous generations of CHK1 inhibitors have encountered significant obstacles in clinical development.
The primary challenge has been toxicity, particularly severe myelosuppression, which includes reductions in blood cell counts such as platelets, white blood cells, and neutrophils. These side effects often restricted dosing levels and limited the ability of earlier CHK1 inhibitors to achieve meaningful therapeutic benefit.
According to study investigator Dr. Timothy A. Yap, Professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, SMP-3124LP was specifically designed to overcome these historical limitations.
He noted that the use of liposomal drug delivery represents an effort to address the major barriers that have hindered CHK1 inhibitor development in the past. For patients who have already exhausted multiple lines of treatment, the approach could potentially offer disease control and clinical benefit without the severe toxicities associated with earlier therapies.
First-in-Human Trial Evaluates Safety and Efficacy
The ongoing Phase 1 portion of the study enrolled 61 patients with selected advanced solid tumors. Participants received intravenous SMP-3124LP every two weeks across four dose levels: 20 mg/m², 40 mg/m², 60 mg/m², and 90 mg/m².
Importantly, the patient population represented a heavily pretreated group with substantial unmet medical needs. More than one-third of enrolled patients had previously received over four lines of therapy, reflecting the advanced nature of their disease and the limited treatment options remaining.
The trial was designed primarily to evaluate safety, tolerability, pharmacokinetics, and dose escalation. However, investigators also assessed preliminary antitumor activity among participants.
As of April 3, 2026, efficacy data were available for 56 evaluable patients, providing the first indication of the therapy’s potential clinical impact.
Encouraging Antitumor Activity Observed
Among the 56 efficacy-evaluable patients, SMP-3124LP demonstrated a disease control rate of 48.2%. Disease control rate measures the percentage of patients who achieve either tumor shrinkage or stabilization of disease and is often used as an early indicator of clinical activity in oncology studies.
The reported disease control included five confirmed partial responses according to RECIST v1.1 criteria and an additional 22 patients who achieved stable disease.
Particularly noteworthy were responses observed in several cancers that are traditionally difficult to treat and often associated with poor outcomes.
Two partial responses were reported in patients with platinum-resistant ovarian cancer, a setting where therapeutic options are often limited following resistance to standard platinum-based chemotherapy. Another two partial responses occurred in patients with squamous cell carcinoma of the anus, while one partial response was observed in a patient with colorectal cancer harboring an FBXW7 mutation.
The FBXW7 mutation has been associated with more aggressive disease biology and poorer clinical outcomes, making the observed response particularly significant.
Additional signs of clinical benefit were also seen among ovarian cancer patients. Two individuals with platinum-resistant ovarian cancer achieved stable disease accompanied by tumor shrinkage exceeding 20%. One of these patients experienced an 88% reduction in CA-125, a commonly used biomarker for monitoring ovarian cancer activity.
Taken together, these findings suggest that SMP-3124LP may possess meaningful antitumor activity across multiple tumor types, particularly in heavily pretreated populations where treatment options are limited.
Safety Results Suggest a Wider Therapeutic Window
One of the most important objectives of the study was determining whether liposomal delivery could improve the safety profile of CHK1 inhibition.
The early data suggest this goal may be achievable.
At the lower dose levels of 20 mg/m² and 40 mg/m², investigators reported no dose-limiting toxicities. This finding is particularly encouraging given the toxicity challenges that have historically plagued this drug class.
Dose-limiting toxicities were observed at higher dose levels of 60 mg/m² and 90 mg/m². These included Grade 4 thrombocytopenia and Grade 3 febrile neutropenia, both known hematologic toxicities associated with DNA damage response inhibitors.
However, researchers noted that these blood-related adverse events were generally transient and manageable. Importantly, none of the observed hematologic toxicities resulted in treatment discontinuation.
The results suggest that the liposomal formulation may help reduce exposure of healthy tissues to the drug while maintaining delivery to tumor sites, potentially expanding the therapeutic window compared with earlier CHK1 inhibitors.
Manageable Infusion-Related Reactions
Another safety observation involved infusion-related reactions, which occurred in approximately 41% of patients.
While this rate may appear notable, investigators emphasized that all infusion-related reactions were classified as either Grade 1 or Grade 2 in severity. These events were successfully managed using standard supportive care measures or by adjusting infusion rates during administration.
The absence of severe infusion-related complications further supports the overall tolerability profile observed in the study.
Researchers believe these findings indicate that SMP-3124LP can be administered safely in a clinical setting while maintaining manageable side effects.
Pharmacokinetic Findings Support the Liposomal Strategy
In addition to efficacy and safety assessments, investigators analyzed pharmacokinetic data to better understand how the drug behaves within the body.
The results provided evidence that the liposomal formulation is functioning as intended.
SMP-3124LP demonstrated a prolonged half-life ranging from approximately 24 to 28 hours, allowing sustained exposure over time. The therapy also exhibited a relatively low volume of distribution between 2.00 and 2.67 liters, a characteristic consistent with liposomal drug delivery systems designed to remain within the vascular compartment before reaching tumors.
Researchers also observed dose-proportional increases in drug exposure across all dose levels evaluated, supporting predictable pharmacokinetic behavior and facilitating future dose optimization efforts.
These findings validate the underlying design strategy behind the therapy and reinforce confidence in the liposomal delivery platform.
Building a Broader Oncology Technology Platform
Company executives view SMP-3124LP as more than a single investigational therapy. Instead, they see it as an example of a broader technological approach aimed at improving targeted cancer treatments through advanced drug delivery systems.
Tsutomu Nakagawa, Ph.D., President and Chief Executive Officer of Sumitomo Pharma America, described the presentation of first-in-human data at ASCO as an important milestone that reflects the company’s commitment to addressing persistent challenges in cancer treatment.
Meanwhile, Dr. Jatin Shah, Chief Medical Officer for Oncology at SMPA, emphasized that the company is actively developing a platform based on liposomal delivery of targeted therapies with the goal of maximizing efficacy while minimizing toxicities.
According to Dr. Shah, the data provide early evidence that selective CHK1 inhibition may be achievable with reduced myelosuppression, the major adverse effect that has historically limited the development of CHK1-targeted therapies.
Although the results remain preliminary and additional clinical evaluation is required, the first data from SMP-3124LP provide encouraging evidence that liposomal CHK1 inhibition could represent a meaningful advancement in the treatment of advanced solid tumors.
The combination of promising disease control, observed tumor responses, manageable safety findings, and favorable pharmacokinetic characteristics supports continued development of the therapy. As the Phase 1/2 study progresses, researchers will seek to further define optimal dosing, expand efficacy assessments, and identify patient populations most likely to benefit.
For patients facing cancers characterized by high replication stress and limited therapeutic options, SMP-3124LP may offer a new avenue of treatment. If future studies confirm these early findings, the therapy could help unlock the long-sought potential of CHK1 inhibition while overcoming many of the challenges that have historically prevented this promising mechanism from reaching its full clinical potential.
About SMP-3124LP
SMP-3124LP is a structurally distinct, investigational, selective checkpoint kinase 1 (CHK1) inhibitor delivered via a PEGylated liposome formulation. CHK1 is a key regulator of the DNA damage response; SMP-3124LP is designed with the goal of inhibiting this protein to induce DNA damage and promote apoptosis (cell death) in cancer cells with high replication stress. The use of liposomal technology may potentially widen the therapeutic window by maximizing drug delivery to tumors while minimizing exposure to healthy tissues, potentially reducing treatment emergent adverse events (TEAEs).
About Sumitomo Pharma
Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.) focused on addressing patient needs in oncology, urology, women’s health, rare diseases, cell & gene therapies and CNS. With products in the U.S., Canada, and Europe, and a diverse pipeline of early- to late-stage assets, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website https://www.us.sumitomo-pharma.com or follow us on LinkedIn.
The Sumitomo corporate symbol mark is a registered trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd.
